NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Oncotelic Therapeutics' Deciparticle™ Nanomedicine Platform and Everolimus Pipeline Expansion
TL;DR
Oncotelic Therapeutics' Deciparticle platform offers a competitive edge by enabling intravenous delivery of hydrophobic drugs, potentially improving efficacy and reducing side effects compared to oral dosing.
The Deciparticle platform works by formulating hydrophobic drugs into uniform nanoparticles for intravenous use, with preclinical data showing reduced gastrointestinal accumulation for Everolimus.
This nanomedicine technology could make cancer treatments more effective and tolerable, improving patient outcomes and quality of life in immunology and oncology.
Oncotelic's platform can package water-resistant drugs like macrolide mTOR inhibitors into tiny nanoparticles, a breakthrough that transforms how challenging medications are delivered intravenously.
Found this article helpful?
Share it with your network and spread the knowledge!
The announcement covers Oncotelic Therapeutics Inc. (OTLC) unveiling its breakthrough Deciparticle™ nanomedicine platform and expanding its Everolimus (Afinitor®) pipeline with new preclinical data showing reduced gastrointestinal drug accumulation.
The Deciparticle™ platform is a scalable nanotechnology that reliably formulates diverse hydrophobic drugs—including macrolide mTOR inhibitors, peptides, and polyketides—into uniform, IV-ready nanoparticles small enough for effective and safe intravenous use.
The data highlighted Sapu003, the intravenous Deciparticle™ formulation of Everolimus (Afinitor®), which in preclinical PK studies showed up to 67-fold reduction in gastrointestinal drug accumulation compared to oral dosing.
This represents a paradigm shift in drug delivery by enabling intravenous administration of water-resistant drugs with reduced side effects, supporting a quickly expanding, modular, cGMP-ready pipeline for improved patient outcomes.
The platform shows high-level compatibility across categories, successfully forming stable, monodisperse particles with all five main macrolide mTOR inhibitors (temsirolimus, sirolimus, ridaforolimus, Everolimus, umirolimus) and key drugs like tacrolimus.
The new data was presented at the 2025 San Antonio Breast Cancer Symposium (SABCS), highlighting the platform's capabilities in transforming drug delivery approaches.
Benefits include reliable formulation of challenging hydrophobic drugs, significant reduction in gastrointestinal accumulation (up to 67-fold for Everolimus), uniform nanoparticle production, and scalability for clinical and commercial applications.
Oncotelic Therapeutics (OTCQB: OTLC) is the company rapidly emerging as a key player in next-generation drug delivery, leveraging its clinical-stage nanomedicine Sapu Nano and the Deciparticle™ platform to advance immunology and oncology treatments.
The latest news and updates relating to OTLC are available in the company's newsroom at ibn.fm/OTLC.
BioMedWire (BMW) released this information as a specialized communications platform focusing on Biotechnology, Biomedical Sciences and Life Sciences sectors, providing wire solutions, editorial syndication, press release enhancement, social media distribution, and corporate communications solutions through the Investor Brand Network.
Curated from InvestorBrandNetwork (IBN)
